Affordable Access

deepdyve-link
Publisher Website

Prevalence and long-term outcome of sub-clinical primary sclerosing cholangitis in patients with ulcerative colitis.

Authors
  • Culver, Emma L1
  • Bungay, Helen K2
  • Betts, Margaret2
  • Forde, Colm2, 3
  • Buchel, Otto4
  • Manganis, Charis1
  • Warren, Bryan F5
  • Cummings, Jr Fraser1, 6
  • Keshav, Satish1
  • Travis, Simon P L1
  • Chapman, Roger W1
  • 1 Translational Gastroenterology Unit, John Radcliffe Hospital, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • 2 Radiology Department, John Radcliffe Hospital and Churchill Hospital, Oxford, UK.
  • 3 Radiology Department, Queen's Hospital, Birmingham, UK.
  • 4 Rondebosch Medical Centre, Cape Town, South Africa. , (South Africa)
  • 5 Histopathology Department, John Radcliffe Hospital, Oxford, UK.
  • 6 Gastroenterology Department, Southampton General Hospital, Southampton, UK.
Type
Published Article
Journal
Liver international : official journal of the International Association for the Study of the Liver
Publication Date
Aug 25, 2020
Identifiers
DOI: 10.1111/liv.14645
PMID: 32841490
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Primary sclerosing cholangitis (PSC) is closely associated with inflammatory bowel disease, particularly ulcerative colitis (UC), with an increased risk of biliary and colorectal malignancy. We sought to clarify the prevalence, characteristics and long-term outcome of sub-clinical PSC diagnosed by magnetic resonance cholangiogram (MRC) in patients with UC and normal liver biochemistry, with or without colorectal dysplasia (CRD). In this prospective case-control study, 70 patients with UC and normal liver function (51 extensive UC, 19 CRD), 28 healthy volunteers (negative-controls) and 28 patients with PSC and cholestasis (positive-controls) underwent MRC and blood evaluation. MRC scans were interpreted blindly by two radiologists who graded individually, the scans as definitive for PSC, possible for PSC or normal. Clinical outcome was assessed by blood monitoring, abdominal imaging and endoscopic surveillance. 7/51 (14%) with extensive UC and 4/19 (21%) with CRD had biliary abnormalities on MRC consistent with PSC. 7/11 (64%) with sub-clinical PSC had isolated intrahepatic duct involvement. Sub-clinical PSC was associated with advanced age (p=0.04), non-smoking (p=0.03), pANCA (p=0.04), quiescent colitis (p=0.02), absence of azathioprine (p=0.04), and high-grade CRD (p=0.03). Inter-observer (kappa=0.88) and intra-observer (kappa=0.96) agreement for MRC interpretation was high. No negative controls were assessed as definite PSC, 4/28 were considered on blinding as possible PSC. During follow-up of sub-clinical PSC (median 10.1(3.1-11.9) years), 4 patients developed abnormal liver biochemistry, 2 had radiological progression of PSC and 7 developed malignancy, including 2 biliary and 1 colorectal carcinoma. Prevalence of sub-clinical PSC appears high in patients with extensive UC and normal liver biochemistry, with or without CRD. Disease progression and malignancy were identified on long-term follow-up. MRC should be considered for all patients with extensive UC or CRD to stratify surveillance. This article is protected by copyright. All rights reserved.

Report this publication

Statistics

Seen <100 times